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Health Organization classification distinguishes
threePTBsubtypes (benign,borderlineandmalig-
nant) [2]. These subtypes present a morphological
continuumfrombenigntomalignant[1].Theclas-
sification is based on a combination of several his-
tological features including: the degree of stromal
atypia,stromalovergrowth,mitoticactivityandtype
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resectionofaxillary lymphnodesor sentinel lymph
nodebiopsy,becausemetastasestothelymphnodes
occurveryrarely[4,6].Therearealsonoindications
for hormonal therapy in patients with PTB. Adju-
vantradiotherapyisrecommendedinborderlineand
malignantPTB, if theresectionmargin is lessthan
1cm[4,5,7].
MostpatientswithdiagnosedPTBhaveagood
prognosis, with local recurrence risk from 17%
in the benign type, up to 27% in the malignant
type [8]. Distant metastases occur even in 22%
of malignant PTB cases [8, 9]. The histological
subtype of PTB is the only prognostic factor in
these patients [6].However, in some individuals,
histologicalfeaturesdonotallowforadequateas-
sessment of the course of the disease (prediction
oflocalrecurrence,distantmetastasesorsurvival).
This research has been undertaken to search for






Material and methods 
Patients




In 4 patients, after re-evaluation of pathology
slidesrecurrenttumorswereclassifiedassarcomas.
Two patients were operated outside the Oncolo-
gyCenter andobtaining tissuematerial fromthe







The study has been reported to the Ethical
Committee at the Regional Medical Chamber in










slideswere evaluatedby apathologist to confirm
thediagnosisandtoselecttheparaffinblocksmost
suitable formolecularanalysis. Inthecaseofpri-




od with Maxwell® RSC Instrument (Promega).




sayKit andQubit 3.0device (ThermoFisher Sci-
entific). Next-generation sequencing (NGS) was
performed on IonTorrent platform. Two hundred
and seven regions in 50 genes that are most of-
tenmutatedinsolidtumorsweresequencedwith
CancerHotspotPanelv2.Librariesforsequencing
were prepared automatically on Chef instrument







wannovar.wglab.org). Variants for which satis-
factory sequencing conditions were obtained and






nih.gov/clinvar) databases variants were classified





Mutation profile of priMary phyllodes tuMors and their local recurrences
Results
Assessment of NGS data 
Next-generation sequencing (NGS) was per-
formedfor10pairsconsistingofprimaryandrecur-





(aged 23-24 years) the data obtained were of low
qualityandmutationanalysisforthesesampleswas
notpossible(TableI).DNAfromthesesampleswas
too fragmented, especially from primary tumor. Fig. 1. Workflowoftheexperimentanddataanalysis
Table I. Qualityof obtained NGS data
pair  
nO.































17.0 99bp 979151 93.64% 3857 97.52% 100 243
M6R(1st)*benign/
borderline
13.8 103bp 991806 95.95% 4106 96.89% 100 344
2 M7PTborderline 13.1 106bp 1288888 97.57% 5517 99.48% 100 30
M8R(3rd)borderline 11.6 113bp 1383908 98.68% 6250 99.48% 100 22
3 M9PTbenign 10.2 107bp 1254256 98.32% 5453 98.25% 100 47
M10R(1st)malignant 7.2 115bp 1387224 98.81% 6365 99.38% 100 22
4 M11PTbenign/
borderline
24.3 89bp 149326 70.56% 408.8 73.29% 68.88 858
M12R(2nd)malignant,
sarcomalikeG3
23.7 96bp 493945 86.83% 1734 88.23% 97.73 1211
5 M13PTbenign/
borderline
16.8 103bp 1008257 97.05% 4217 97.50% 100 331
M14R(3rd)malignant 13.6 107 bp 1430807 98.77% 6260 87.01% 100 41
6 M15PTborderline 17.7 95 bp 502980 85.67% 1748 88.14% 100 987
M16R(2nd)malignant 7.50 111bp 1268905 98.60% 5679 99.48% 100 18
7 M17PTc.benign** 10.7 112 bp 1165877 98.41% 5271 99.48% 100 17
M18PTc.malignant 10.7 114 bp 909468 98.21% 3997 99.48% 100 19
M19 R(1st) malignant 10.5 104 bp 1088939 96.62% 4569 99.17% 100 89
8 M20PTmalignant 6.8 106 bp 1353842 98.45% 5859 87.84% 100 55
M21R(1st)malignant 6.6 109 bp 1371358 98.70% 6070 89.48% 100 39
9 M23PTmalignant 6.6 113 bp 1385681 98.67% 6309 98.84% 100 17
M24R(1st)malignant 5.6 109 bp 1295685 98.49% 5714 86.35% 100 43
10 M25PTmalignant 24.7 126 bp 5510 33.47% 7.02 65.13% 0.21 17
M26R(1st)malignant 24.2 133 bp 148752 65.42% 382.3 75.63% 69.03 904
*– the number of tested recurrence, ** c – component, PT – primary tumor, R – recurrence
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es should be considered as sequencing errors (low
sequencingparameters)andchanges typical for the
formalin-fixedmaterial(changeG>AandT>C).






were found in CDKN2A gene (Table II). In two
pairs, the same variant creating the STOP codon
and causing synthesis of the truncated protein was
detected. The other variant in CDKN2A gene was





onepatient, twoclearly separated components:be-
nign and malignant were identified in the primary



























*– the number of tested recurrence, ** c – component, PT – primary tumor, R – recurrence
in the malignant component. The same mutations

























ry tumour and also in matched local recurrence in
CDKN2A (in 3 pairs), PTEN (1 pair) and TP53 










tumors than in fibroadenomas, benign and border-







genes” for phyllodes tumours: TP53 (mutation in
12%),EGFR(6%),PTEN(4%).Inourstudy,most
frequently mutated gene was CDKN2A, in which
mutation were observed both in primary tumors
andlocalrecurrences.Mutationsorhomozygousde-
letions in CDKN2A gene in phyllodes tumour are
also reportedbyother authors [12,13,14].Tan et 
al.studiedagroupof20casesofphyllodestumour,
including 11 cases with no recurrence and 9 with
local recurrence/metastases. In this group, homo-
































mark of progression. In order to determine if this
variant is associated with progression, the frequen-
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